Prelude Therapeutics Incorporated PRLD PHARMA
Company Overview
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.13.
Recent Developments
- Dec 2025 Revenue of $12.14M (+73.4% YoY); net profit $-99.50M.
- Trailing 12 Months Year-on-year growth — revenue +73.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 73.43% |
Stock Price Performance
| 1 Year: | +484.34% |
| 6 Months: | +71.52% |
| 3 Months: | +38.02% |
| 1 Month: | +8.16% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)46.85 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRLD Prelude Therapeutics Incorporated PHARMA | 5.30 | -7.26 | $344.06M | 0.00% | -118.39% | -57.73% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.00M | 0 | 0 | 6.50M | 5.64M | 4.58M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.61M | 32.19M | 26.92M | 22.99M | 18.76M |
| Operating Income | - | - | -6.88M | -9.74M | -11.44M | -18.14M | -21.97M | -27.92M | -30.84M | -30.29M | -29.46M | -30.41M | -29.11M | -32.40M | -33.38M | -34.34M | -37.16M | -34.38M | -34.61M | -32.19M | -20.42M | -17.35M | -14.18M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -34.17M | -31.76M | -19.99M | -16.93M | -13.79M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -32.09M | -31.23M | -19.73M | -16.46M | -10.38M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -5.24M | -5.56M | -6.73M | -9.51M | -11.41M | -16.76M | -21.30M | -26.86M | -30.69M | -29.46M | -27.37M | -29.96M | -27.72M | -30.43M | -30.61M | -31.43M | -34.74M | -32.27M | -32.09M | -31.23M | -19.73M | -16.46M | -10.38M |
| Diluted EPS | - | - | - | - | - | - | - | -0.58 | -0.66 | -0.63 | -0.58 | -0.63 | -0.58 | -0.54 | -0.45 | -0.42 | -0.46 | -0.43 | -0.42 | -0.41 | -0.26 | - | -0.13 |
| R&D Expense | - | - | 5.49M | 8.54M | 9.78M | 15.29M | 16.47M | 22.41M | 22.72M | 22.82M | 21.31M | 22.89M | 21.83M | 24.97M | 26.26M | 27.41M | 29.51M | 29.46M | 28.82M | 25.78M | 21.71M | - | 13.60M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 7.00M | 12.14M |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 123.54M | 132.28M | 146.71M | 116.71M |
| Operating Income | -28.11M | -58.76M | -113.73M | -123.54M | -132.28M | -139.71M | -104.57M |
| EBITDA | - | - | - | -122.22M | -131.11M | -137.94M | -102.86M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -115.44M | -121.83M | -127.17M | -99.50M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -27.57M | -56.93M | -111.69M | -115.44M | -121.83M | -127.17M | -99.50M |
| Diluted EPS | - | - | -2.43 | -2.44 | -2.02 | -1.68 | -1.29 |
| R&D Expense | 24.28M | 48.18M | 86.78M | 92.89M | 103.39M | 118.00M | 94.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 21.87M | 223.59M | - | 220.50M | 277.67M | 175.51M | 141.31M |
| Current Assets | - | - | - | - | 204.38M | 235.59M | 135.90M | 105.69M |
| Cash & Equivalents | - | 18.88M | 218.31M | - | 30.61M | 25.29M | 12.47M | 35.26M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.84M | 11.41M | - | 25.06M | 40.58M | 44.06M | 72.68M |
| Current Liabilities | - | 4.83M | 11.38M | - | 21.70M | 21.83M | 25.64M | 52.99M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 1.83M | 16.89M | 18.02M | 17.79M |
| Total Equity | -22.69M | -49.41M | 212.18M | - | 195.44M | 237.09M | 131.46M | 68.64M |
| Shares Outstanding | - | - | - | - | 47.90M | 54.91M | 55.15M | 62.95M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -25.66M | -46.18M | - | -83.73M | -107.06M | -102.89M | -56.30M |
| Investing Cash Flow | -780.00K | -621.00K | - | 81.69M | -34.65M | 90.19M | 53.46M |
| Financing Cash Flow | 29.73M | 246.23M | - | 815.00K | 136.40M | -120.00K | 24.82M |
| Capital Expenditure | -780.00K | -621.00K | - | -3.02M | -3.51M | -764.00K | -67.00K |
| Free Cash Flow | -26.45M | -46.80M | - | -86.75M | -110.58M | -103.65M | -56.37M |
| Net Change in Cash | - | - | - | -1.22M | -5.31M | -12.82M | 21.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | -1,995.9% | -861.3% |
| Net Margin % | - | - | - | - | - | -1,816.8% | -819.6% |
| ROE % | 55.8% | -26.8% | - | -59.1% | -51.4% | -96.7% | -145.0% |
| ROCE % | -165.0% | -27.7% | - | -62.1% | -51.7% | -93.2% | -118.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Orbimed Advisors LLC. | 24.32% | 19.40M | $94.50M |
| 2 | Baker Bros. Advisors, LP | 12.69% | 10.12M | $49.30M |
| 3 | RA Capital Management, L.P. | 8.11% | 6.48M | $31.54M |
| 4 | Soleus Capital Management, L.P. | 4.23% | 3.38M | $16.45M |
| 5 | Kynam Capital Management, LP | 3.03% | 2.42M | $11.76M |
| 6 | Vanguard Capital Management LLC | 2.52% | 2.01M | $9.79M |
| 7 | Blackrock Inc. | 2.25% | 1.80M | $8.75M |
| 8 | Sphera Funds Management Ltd. | 1.28% | 1.02M | $4.97M |
| 9 | Two Sigma Investments, LP | 1.24% | 993.37K | $4.84M |
| 10 | Adar1 Capital Management, LLC | 1.13% | 900.90K | $4.39M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRLD
Prelude Therapeutics: A Prognosis After Year Long Rally (NASDAQ:PRLD) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPX3dEN3pSRUZ5d0RtX1c0bzdVLUVOY1VUUElYaGp2Um1FZXZSTmJvQjAtdnFYWTZ5eUtzQ2RNV2NremVULXhyOU4wVW9fZ0t2OFBxdHVmem5kNVFJRV9zTmNNa0hraFZJTHZuOFk2eGpjMUFGNVlmVEJCQmVOQ1B5WjNzS0REajNPVEFpTX…
(PRLD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPa0NRaUl5S3hxd2djSnNWcFZ2dEFfWlNubGlEd3JGcFM0dU9qM3F4a2lhNFdOcUNwSXN1TFdNTUhpVUZpYlNsNnltYk94MGlwZW1BaEkxRVFCQjlfRlVvMlV3THVGVFBRXzZyUVYyQW4ycVlZMnZlTGROSVVJQVJVaGZLMXFYdXdEUnpOVn…
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQeno3ZWVCaERGbGxBVVJYTmZ5TnB1S2JuVEFtWkxRMHNKMGstaUN3MVZRbW5RLXdsMHBRWFZkMnJ3VGRSQjhvdjd2N1lCbzlTMkliMFV1dmhJTF94WGlOQko4Y2tOeWxuZjJiN1ljRElSdE55TjFCb1hUeVl5cVdlUWxpa0ZuVC1Pb1I1Sj…
Why Did PRLD Stock Surge 13% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxPVnlSNVFQalllSk5Yb0lyZWpRV2k3bnJVZUlOUHpfd1RwekFrSTBmZnE0ODJ0QkYwc0VJT3Vtd2t1Z1M3ajBSNTJDaFdWQkxkY0VCdUVBVmFicFhHaEw4ZVk1ZmdoSnExVmlGamtrRFRlVDBRQWNONzdpamxFbkdpUlYtY09PUy11djdZbD…
$PRLD stock is up 19% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOUWV0QzFSTE9Ka0VEOEdqQk9jZW9VX0lWeUpGeHdZMVNHVFU5XzB5a0pGOVM3LUtLYnhFdmlEaUZ1OEhqM2JvWkx2X3RJRFQ1blJQY2RtRWh6MGwxanJVcVBhZV9tQkx5YS0yNUJDLTFyUXJDR3ViRnBEWkhHWFFMYUtSZUJObGlEbG9fVl…
Prelude Therapeutics (PRLD) Stock Rallies As Losses Ease But Milestones Remain Unclear - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxOYkNpOUJMc1BFZXliSUNVbF95NmpUdnBDMU4wZVFIam83T21jQlg4aE5ZY0txZFZXa2xiY18weTlaWXBLSlFoaUtOa2d5SjhCTE53SWlEdTF3Q2hwcGRvd09ObGVpbnhwVV9WdFM5djdYUFdoWWE5aVFlZEFOVnVHc2o1VTQ3bzl6TkF2Mn…
PRLD — Frequently Asked Questions
What is the current share price of Prelude Therapeutics Incorporated (PRLD)?
As of 2026-09-19 21:16 PDT, Prelude Therapeutics Incorporated (PRLD) trades at $5.30 on NasdaqGS. Its 52-week range is $0.87 to $6.63.
What is the market capitalisation of PRLD?
Prelude Therapeutics Incorporated (PRLD) has a market capitalisation of $344.06M on NasdaqGS.
What is the P/E ratio of PRLD?
PRLD trades at a trailing price-to-earnings (P/E) ratio of -7.26. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 3.75.
What is the return on equity (ROE) of PRLD?
PRLD has a return on equity (ROE) of -57.73%. Its return on capital employed (ROCE) is -118.39%.
Is PRLD a good stock to buy?
This page provides a data-driven analysis of Prelude Therapeutics Incorporated (PRLD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.